For diabetes mellitus. Sold as Admelog, Admelog Solostar. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Insulin Lispro (sold as Admelog, Admelog Solostar), first approved Dec 11, 2017, with 0 new uses approved and 0 published complete response letters.
| Humalog Kwikpen U-100 | Part D | $334M | 0% | 435,987 |
| Humalog Kwikpen U-200 | Part D | $263M | +15% | 48,138 |
| Insulin Lispro Kwikpen U-100 | Part D | $194M | +26% | 336,434 |
| Humalog | Part D | $94.5M | -4% | 130,197 |
| Admelog Solostar | Part D | $41.7M | +23% | 52,811 |
| Insulin Lispro | Part D | $24.9M | +42% | 128,003 |
| Admelog | Part D | $11.0M | +12% | 13,372 |
| Humalog Junior Kwikpen | Part D | $3.5M | +13% | 7,210 |
| Insulin Lispro Junior Kwikpen | Part D | $2.2M | +42% | 5,734 |
| Humalog Tempo Pen U-100 | Part D | $236K | +5% | 610 |
| Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)Diabetes in Pregnancy, Gestational Diabetes · Rutgers, The State University of New Jersey | Not applicable | Recruiting | Sep 12, 2025 |
| Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?Brain Insulin Sensitivity, Healthy Controls · Centre for Addiction and Mental Health | Phase 4 | Recruiting | Aug 7, 2025 |
| A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesDiabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 · Eli Lilly and Company | Phase 1 | Recruiting | Apr 25, 2025 |
| A Trial of Three- and Seven-days Insulin Infusions SetType 1 Diabetes · Steno Diabetes Center Copenhagen | Not applicable | Recruiting | Aug 1, 2024 |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesGestational Diabetes Mellitus, Pregnancy, High Risk · Ohio State University | Phase 4 | Recruiting | Jun 6, 2024 |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)Gestational Diabetes, Pregnancy Related · Thomas Jefferson University | Not applicable | Recruiting | May 17, 2024 |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational DiabetesGestational Diabetes, Pregnancy Related · Thomas Jefferson University | Not applicable | Recruiting | May 17, 2024 |
| Effects of Antipsychotics on Brain Insulin Action in FemalesInsulin Resistance, Menstrual Cycle · Centre for Addiction and Mental Health | Not applicable | Active, not recruiting | Feb 9, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 11, 2017 | Admelog, Admelog SolostarBLA 209196 · New formulation or manufacturer | Sanofi-Aventis US | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi-Aventis US